Eikon Therapeutics completed an upsized $381 million initial public offering, selling 21.2 million shares at $18 apiece to fund clinical development of its oncology pipeline. The California company plans to prioritize trials of EIK1001, a TLR7/8 immune modulator paired with pembrolizumab, and several PARP1 inhibitors and a WRN helicase inhibitor now in early clinical testing. The IPO marks one of the largest biotech listings since 2024 and signals renewed investor appetite for experienced drug developers pursuing oncology immune-modulatory and DNA‑repair targets.